Preliminary Efficacy and Safety Data from the Phase 2 Trial of Riliprubart (SAR445088), a Humanized Monoclonal Antibody Targeting Complement C1s, in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (S15.008)
Luís Querol, Richard A. Lewis, Hans‐Peter Hartung, P. van Doorn, Erik Wallstroem, Xiaodong Luo, Miguel Alonso‐Alonso, Nazem Atassi, Richard AC Hughes
Abstract
Report preliminary efficacy and safety results for riliprubart, a novel complement C1s-inhibitor, in people with CIDP.
Topics & Concepts
Chronic inflammatory demyelinating polyneuropathyMedicineMonoclonal antibodyComplement (music)ImmunologyAntibodyBiologyComplementationPhenotypeGeneBiochemistryPeripheral Neuropathies and DisordersMyasthenia Gravis and ThymomaHereditary Neurological Disorders